News und Analysen
Aurinia Prices US$166.7 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Distributed Bio Launches Cosmic Antibody Library, Provides Charles River Clients Exclusive Access
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the Company will provide clients exclusive access to the new Cosmic antibody library launched by Distributed Bio, Inc., a
Transgene Announces Investor Meetings for January 2020
Regulatory News:
Transgene (Paris:TNG) today announces that Management will participate in the upcoming investor events set out below.
Transgene will meet institutional investors at the LifeSci
ArQule: +100% nach Milliarden-Übernahme
Das amerikanische Pharmakonglomerat Merck & Co. (WKN: A0YD8Q) akquiriert den Biotechforscher ArQule (WKN: 903396) für 20 US-Dollar je Aktie. Merck legt für die Übernahme 2,7 Milliarden US-Dollar in
Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today
Lantheus Enters into Strategic Collaboration with CarThera for Use of Microbubbles in Combination with SonoCloud® System for Treatment of Glioblastoma
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative
ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced final results from the phase 1 study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant
Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the first three patients treated in the Phase 1/2 THALES study evaluating
Aurinia Announces Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
The Quinze-Vingts Hospital and GenSight Biologics Announce a First Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191208005050/en/
The National Eye Hospital (CHNO) of the Quinze-Vingt
Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that updated results from SPiReL, an ongoing Phase 2
Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the Phase 1/2 Alta study evaluating
Navidea Biopharmaceuticals Announces $1.9 Million Private Placement
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Agilent Ranked Among Top Four Best Workplaces in Greater China and Receives Certification as a Best Workplace for Women in Greater China
Agilent Technologies, Inc. (NYSE: A) today announced it has been selected as one of the top four “Best Workplaces™ in Greater China” by the Great Place to Work® (GPTW) Institute. The company has
Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo
Carl Zeiss Meditec: Aktie stürzt ab – Quittung für die "Rekordzahlen"?
Rekordjahr für die Carl Zeiss Meditec AG (WKN: 531370): Noch nie erzielte der Medizintechnik-Konzern so gute Zahlen wie in 2018/2019. An der Börse wird die Aktie heute mit einem Kursrutsch um -8,54%
Vertex Pharmaceuticals: Starke Aktie aus starkem Sektor
Relativ unbemerkt von der breiten Öffentlichkeit konnte der NASDAQ Biotechnology Index (NBI) zuletzt in der Spitze um fast +25% zulegen. Einer der Treiber dieser Kursrally war dabei, mal wieder, das
Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
MorphoSys: Anleger wetten wohl auf das Blutkrebsmedikament
Bekanntlich halte ich Evotec und MorphoSys (WKN: 663200) für die beiden besten deutschen Biotechunternehmen, so dass diese beiden Aktien für mich die beiden besten deutschen Biotechaktien sind
MagForce: Neues Therapiezentrum in Ostdeutschland
Eine der interessantesten Stories unter den Smallcaps in Deutschland liefert schon seit Jahren die Berliner MagForce (WKN: A0HGQF). Dies sah schon vor einiger Zeit auch der bekannte Venture
LivaNova to Present New Data on Vagus Nerve Stimulation Therapy System at the American Epilepsy Society 2019 Annual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present new registry data from two patient populations benefiting from Vagus Nerve
Sartorius Acquires a Majority Stake in Cell Culture Media Specialist Biological Industries
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, signed an agreement to acquire a majority stake in the Israeli cell culture media developer
Sartorius übernimmt Mehrheit am Zellkulturmedien-Spezialisten Biological Industries
Sartorius, ein international führender Partner der biopharmazeutischen Forschung und Industrie, hat eine Vereinbarung zum Erwerb der Mehrheit an dem israelischen Zellkulturmedien-Entwickler und
Charles River Laboratories Updates Tumor Model Compendium
Charles River Laboratories International, Inc. (NYSE: CRL) today announced updates to its online Tumor Model Compendium. Charles River’s cancer model database provides access to a comprehensive
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and